microdosing glp-1 receptor agonists Explained Micro-dosing GLP-1 for inflammation reduction?

This is a testament to the power of a sustained, long-term approach

February 2, 2026: FDA Published Second Safety Label Change of 2026 for Zepbound Eli Lillys popular weight-loss drug Zepbound had a second safety label update in January 2026

sulfonylureas, meglitinides), liraglutide increases the risk of hypoglycemia

Its better to switch as infrequently as possible to avoid confusion around dosing differences between formulas, Watson says

This may overload the manufacturer and the shortage could be re-designated

The same precursor is differentially cleaved by two prohormone convertases depending on the tissue context